Tumor markers in breast cancer

Y. Harada, N. Ohuchi, T. Ishida, K. Ohnuki

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Many serological markers have been utilized to indicate the status, risk, or presence of breast cancer. In May 1996, the American Society of Clinical Oncology (ASCO) convened a Tumor Marker Panel and determined clinical practice guidelines for the use of tumor markers in breast cancer. Eight markers containing carcinoembryonic antigen (CEA) and CA15-3 were evaluated and assigned by expert reviewers to be valuable markers of breast cancer. CA15-3 recognizes a mucin-like glycoprotein, MUC-1, which is frequently expressed in breast cancer tissues. BCA225, which may recognize antigens similar to MUC-1 glycoprotein, are sensitive and specific markers for breast cancer. However, it is not recommended to measure the 2 markers in combination. The measurement of carboxy-terminal telopeptide of type I collagen (I CTP) is worthwhile as a serological diagnostic method of bone metastasis from breast cancer. Other markers such as erbB-2, CYFRA 21-1 and PTHrP are candidates for clinical utilization as tumor markers in breast cancer.

Original languageEnglish
Pages (from-to)1035-1040
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume28
Issue number7
Publication statusPublished - 2001 Jul

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor markers in breast cancer'. Together they form a unique fingerprint.

Cite this